A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression

Yasumoto Yamasaki, Hiroshi Tazawa, Yuuri Hashimoto, Toru Kojima, Shinji Kuroda, Shuuya Yano, Ryosuke Yoshida, Futoshi Uno, Hiroyuki Mizuguchi, Akira Ohtsuru, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomerase-specific oncolytic adenovirus, OBP-301, that causes cell death in human cancer cells with telomerase activities. Here, we further modified OBP-301 to express the wild-type p53 tumour suppressor gene (OBP-702), and investigated whether OBP-702 induces stronger antitumour activity than OBP-301. The antitumour effect of OBP-702 was compared to that of OBP-301 on OBP-301-sensitive (H358 and H460) and OBP-301-resistant (T.Tn and HSC4) human cancer cells. OBP-702 suppressed the viability of both OBP-301-sensitive and OBP-301-resistant cancer cells more efficiently than OBP-301. OBP-702 caused increased apoptosis compared to OBP-301 or a replication-deficient adenovirus expressing the p53 gene (Ad-p53) in H358 and T.Tn cells. Adenovirus E1A-mediated p21 and MDM2 downregulation was involved in the apoptosis caused by OBP-702. Moreover, OBP-702 significantly suppressed tumour growth in subcutaneous tumour xenograft models compared to monotherapy with OBP-301 or Ad-p53. Our data demonstrated that OBP-702 infection expressed adenovirus E1A and then inhibited p21 and MDM2 expression, which in turn efficiently induced apoptotic cell death. This novel apoptotic mechanism suggests that the p53-expressing OBP-702 is a promising antitumour reagent for human cancer and could improve the clinical outcome.

Original languageEnglish
Pages (from-to)2282-2291
Number of pages10
JournalEuropean Journal of Cancer
Volume48
Issue number14
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Adenoviridae
Neoplasms
Telomerase
Cell Death
Oncolytic Viruses
Apoptosis
Adenoviridae Infections
p53 Genes
Tumor Suppressor Genes
Heterografts
Cause of Death
Down-Regulation
Growth
Genes

Keywords

  • Apoptosis
  • Oncolytic adenovirus
  • P21
  • P53
  • Telomerase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. / Yamasaki, Yasumoto; Tazawa, Hiroshi; Hashimoto, Yuuri; Kojima, Toru; Kuroda, Shinji; Yano, Shuuya; Yoshida, Ryosuke; Uno, Futoshi; Mizuguchi, Hiroyuki; Ohtsuru, Akira; Urata, Yasuo; Kagawa, Shunsuke; Fujiwara, Toshiyoshi.

In: European Journal of Cancer, Vol. 48, No. 14, 09.2012, p. 2282-2291.

Research output: Contribution to journalArticle

Yamasaki, Yasumoto ; Tazawa, Hiroshi ; Hashimoto, Yuuri ; Kojima, Toru ; Kuroda, Shinji ; Yano, Shuuya ; Yoshida, Ryosuke ; Uno, Futoshi ; Mizuguchi, Hiroyuki ; Ohtsuru, Akira ; Urata, Yasuo ; Kagawa, Shunsuke ; Fujiwara, Toshiyoshi. / A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. In: European Journal of Cancer. 2012 ; Vol. 48, No. 14. pp. 2282-2291.
@article{fde407de683241dcbd2694dc2dd7daa4,
title = "A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression",
abstract = "Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomerase-specific oncolytic adenovirus, OBP-301, that causes cell death in human cancer cells with telomerase activities. Here, we further modified OBP-301 to express the wild-type p53 tumour suppressor gene (OBP-702), and investigated whether OBP-702 induces stronger antitumour activity than OBP-301. The antitumour effect of OBP-702 was compared to that of OBP-301 on OBP-301-sensitive (H358 and H460) and OBP-301-resistant (T.Tn and HSC4) human cancer cells. OBP-702 suppressed the viability of both OBP-301-sensitive and OBP-301-resistant cancer cells more efficiently than OBP-301. OBP-702 caused increased apoptosis compared to OBP-301 or a replication-deficient adenovirus expressing the p53 gene (Ad-p53) in H358 and T.Tn cells. Adenovirus E1A-mediated p21 and MDM2 downregulation was involved in the apoptosis caused by OBP-702. Moreover, OBP-702 significantly suppressed tumour growth in subcutaneous tumour xenograft models compared to monotherapy with OBP-301 or Ad-p53. Our data demonstrated that OBP-702 infection expressed adenovirus E1A and then inhibited p21 and MDM2 expression, which in turn efficiently induced apoptotic cell death. This novel apoptotic mechanism suggests that the p53-expressing OBP-702 is a promising antitumour reagent for human cancer and could improve the clinical outcome.",
keywords = "Apoptosis, Oncolytic adenovirus, P21, P53, Telomerase",
author = "Yasumoto Yamasaki and Hiroshi Tazawa and Yuuri Hashimoto and Toru Kojima and Shinji Kuroda and Shuuya Yano and Ryosuke Yoshida and Futoshi Uno and Hiroyuki Mizuguchi and Akira Ohtsuru and Yasuo Urata and Shunsuke Kagawa and Toshiyoshi Fujiwara",
year = "2012",
month = "9",
doi = "10.1016/j.ejca.2011.12.020",
language = "English",
volume = "48",
pages = "2282--2291",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression

AU - Yamasaki, Yasumoto

AU - Tazawa, Hiroshi

AU - Hashimoto, Yuuri

AU - Kojima, Toru

AU - Kuroda, Shinji

AU - Yano, Shuuya

AU - Yoshida, Ryosuke

AU - Uno, Futoshi

AU - Mizuguchi, Hiroyuki

AU - Ohtsuru, Akira

AU - Urata, Yasuo

AU - Kagawa, Shunsuke

AU - Fujiwara, Toshiyoshi

PY - 2012/9

Y1 - 2012/9

N2 - Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomerase-specific oncolytic adenovirus, OBP-301, that causes cell death in human cancer cells with telomerase activities. Here, we further modified OBP-301 to express the wild-type p53 tumour suppressor gene (OBP-702), and investigated whether OBP-702 induces stronger antitumour activity than OBP-301. The antitumour effect of OBP-702 was compared to that of OBP-301 on OBP-301-sensitive (H358 and H460) and OBP-301-resistant (T.Tn and HSC4) human cancer cells. OBP-702 suppressed the viability of both OBP-301-sensitive and OBP-301-resistant cancer cells more efficiently than OBP-301. OBP-702 caused increased apoptosis compared to OBP-301 or a replication-deficient adenovirus expressing the p53 gene (Ad-p53) in H358 and T.Tn cells. Adenovirus E1A-mediated p21 and MDM2 downregulation was involved in the apoptosis caused by OBP-702. Moreover, OBP-702 significantly suppressed tumour growth in subcutaneous tumour xenograft models compared to monotherapy with OBP-301 or Ad-p53. Our data demonstrated that OBP-702 infection expressed adenovirus E1A and then inhibited p21 and MDM2 expression, which in turn efficiently induced apoptotic cell death. This novel apoptotic mechanism suggests that the p53-expressing OBP-702 is a promising antitumour reagent for human cancer and could improve the clinical outcome.

AB - Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomerase-specific oncolytic adenovirus, OBP-301, that causes cell death in human cancer cells with telomerase activities. Here, we further modified OBP-301 to express the wild-type p53 tumour suppressor gene (OBP-702), and investigated whether OBP-702 induces stronger antitumour activity than OBP-301. The antitumour effect of OBP-702 was compared to that of OBP-301 on OBP-301-sensitive (H358 and H460) and OBP-301-resistant (T.Tn and HSC4) human cancer cells. OBP-702 suppressed the viability of both OBP-301-sensitive and OBP-301-resistant cancer cells more efficiently than OBP-301. OBP-702 caused increased apoptosis compared to OBP-301 or a replication-deficient adenovirus expressing the p53 gene (Ad-p53) in H358 and T.Tn cells. Adenovirus E1A-mediated p21 and MDM2 downregulation was involved in the apoptosis caused by OBP-702. Moreover, OBP-702 significantly suppressed tumour growth in subcutaneous tumour xenograft models compared to monotherapy with OBP-301 or Ad-p53. Our data demonstrated that OBP-702 infection expressed adenovirus E1A and then inhibited p21 and MDM2 expression, which in turn efficiently induced apoptotic cell death. This novel apoptotic mechanism suggests that the p53-expressing OBP-702 is a promising antitumour reagent for human cancer and could improve the clinical outcome.

KW - Apoptosis

KW - Oncolytic adenovirus

KW - P21

KW - P53

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=84865474540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865474540&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.12.020

DO - 10.1016/j.ejca.2011.12.020

M3 - Article

C2 - 22244827

AN - SCOPUS:84865474540

VL - 48

SP - 2282

EP - 2291

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 14

ER -